Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bersacapavir in Hepatic Impairment
NCT04208399Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bersacapavir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Plasma Concentration of JNJ-56136379 at Day 21. Started Jan 2020; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04208399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208399.